Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 14/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 14/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 11/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SI | P14410 | 1/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371980 | 0.84 | GAA (0.49) | MAP4K1PIM1PIM3PIM2MGAM | |
| SCHEMBL1710267 | 0.80 | METAP2 (0.42) | PIM1PIM3PIM2 | |
| SCHEMBL1710258 | 0.80 | MAP4K1 (0.53) | MAP4K1 | |
| SCHEMBL17691567 | 0.76 | KMT2A (0.48) | — | |
| SCHEMBL8404376 | 0.72 | CYP2A6 (0.39) | — | |
| SCHEMBL12371976 | 0.70 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL3530216 | 0.69 | NPC1 (0.38) | MGAMGAASIMGAM2ACHE | |
| SCHEMBL856477 | 0.69 | EGFR (0.39) | MGAMGAASIMGAM2 | |
| SCHEMBL19466048 | 0.69 | PARP1 (0.37) | GAA | |
| SCHEMBL2916502 | 0.69 | FGFR1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759338-B2 | Heterocyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195956-A1 | Heterocyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | MAP4K1 37/4885PIM1 1/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.